172 states, multiple candidate vaccines work with Covax
- by Joy Garcia
- in Medicine
- — Aug 25, 2020
It is said that the new vaccine is quite different from the COVID-19 vaccines now in the making, as this one is administered through the nose, which is, in most cases, the initial site of infection. "There is presently no cure for the highly contagious novel coronavirus that causes COVID-19 and our best plan of attack is to find a vaccine that can help protect people from getting it in the first place". According to the draft, the national mission will work towards bringing to the citizens of the country a safe, efficacious, affordable and accessible Covid vaccine at the earliest with a focus on "AatmaNirbhar Bharat" and also fulfil the commitment of serving not just the country but the entire globe. "Initially, when there will be a limited supply, it is importance to provide the vaccine to those at highest risk around the world".
Italy kicked off human trials of a potential COVID-19 vaccine on Monday, joining a global effort to develop a response to the virus which has shown signs of resurging in Europe.
China, Russia, and the U.S. have not been named part of it. Our Phase 3 trial of NanoFlu, which we reported in March of 2020, provided us with a deep understanding of the unique needs of older adults, who are particularly vulnerable to COVID-19.
"There are clear provisions in Article 20 of our country's vaccine law".
EpiVacCorona: Russia’s second COVID-19 vaccine shows promise
The agency has said that the vaccine produces an immune response after double administration with an interval of 14-21 days. The companies revealed that the side effects of the latest vaccine BNT162b2 are less visible.
The aim is to boost the immunity of specific groups of people, including medical workers and those who work at food markets and in the transportation and service sectors, Zheng Zhongwei, a National Health Commission official, told state TV in an interview aired late on Saturday.
The goal of introducing the vaccine on an emergency basis is to "build immune barriers" among medical workers and key staff to ensure that cities continue to function normally, Zheng said. "Then the entire city's operation has a stable guarantee". The need for a vaccine is rising with the number of global coronavirus deaths surpassing 800,000. Developed by the Moscow-based Gamaleya Research Institute and the Russian Defence Ministry, the vaccine was officially registered by the Russian government on 11 August. The special permission lasts for one year and will only apply to military personnel. The goal is to deliver 2 billion effective vaccines by the end of next year.
In terms of security, current studies assess the possible short-term undesired effects , but Soumya Swaminathan clarified that any approved vaccine must be evaluated in the long term "because there are some side effects that can only occur after a certain period of time".
